Drugs / BECLANORSEN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00285103 | Jun 2005 → Dec 2007 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Santaris Pharma A/S | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BECLANORSEN | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068623 ↗ |
| Known as | SPC2996 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00285103 ↗ |
| Action | Inhibit | “By lowering the Bcl-2 protein in these tumour cells” NCT00285103 ↗ |
| Modality | Antisense oligonucleotide | “SPC2996, a LNA antisense molecule against Bcl-2” NCT00285103 ↗ |
| Target | BCL2 | “a LNA antisense molecule against Bcl-2” NCT00285103 ↗ |